Overview

A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Status:
Recruiting

Trial end date:
2024-05-31

Target enrollment:

Participant gender:

Summary

The purpose of the study is to test the efficacy, safety and tolerability of brivaracetam monotherapy in study participants 2 to 25 years of age inclusive with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).

Phase:

Phase 3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

Brivaracetam